ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
Other Current Assets
ExpreS2ion Biotech Holding AB
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Other Current Assets
kr1.6m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Other Current Assets
kr417.8m
|
CAGR 3-Years
192%
|
CAGR 5-Years
114%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Other Current Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Other Current Assets
kr74m
|
CAGR 3-Years
16%
|
CAGR 5-Years
46%
|
CAGR 10-Years
23%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Other Current Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
Other Current Assets
kr296.5m
|
CAGR 3-Years
168%
|
CAGR 5-Years
104%
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Other Current Assets?
Other Current Assets
1.6m
SEK
Based on the financial report for Dec 31, 2025, ExpreS2ion Biotech Holding AB's Other Current Assets amounts to 1.6m SEK.
What is ExpreS2ion Biotech Holding AB's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
24%
Over the last year, the Other Current Assets growth was 37%. The average annual Other Current Assets growth rates for ExpreS2ion Biotech Holding AB have been -46% over the past three years , 24% over the past five years .
